Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience, Inc. (Nasdaq: NAGE), formerly ChromaDex Corp., announced its corporate rebranding and new ticker symbol effective March 19, 2025. The company, a global authority on NAD+ with over 25 years of legacy, focuses on healthy aging through its flagship product Niagen, a patented nicotinamide riboside (NR) ingredient.
The company reported strong financial performance with full-year 2024 net sales of $99.6 million, up 19% year-over-year, and maintains $44.7 million in cash with no debt. Their product portfolio includes Tru Niagen, the #1 NAD+ boosting oral supplement in the US, and Niagen Plus, a pharmaceutical-grade IV and injectable version available by prescription at 475 clinics nationwide.
The rebranding reflects the company's evolution and success in NAD+ research, supported by over 35 human clinical studies on Niagen. The executive team will commemorate this milestone at the Nasdaq Closing Bell Ceremony on March 19, 2025.